Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals (ACADResearch Report), BridgeBio Pharma (BBIOResearch Report) and AN2 Therapeutics, Inc. (ANTXResearch Report) with bullish sentiments.

ACADIA Pharmaceuticals (ACAD)

Leerink Partners analyst Marc Goodman maintained a Buy rating on ACADIA Pharmaceuticals on April 18. The company’s shares closed last Tuesday at $21.72.

According to TipRanks.com, Goodman is a 1-star analyst with an average return of -0.2% and a 44.3% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Amylyx Pharmaceuticals Inc, and Intra-Cellular Therapies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $29.75 average price target, representing a 38.2% upside. In a report issued on April 6, RBC Capital also maintained a Buy rating on the stock with a $34.00 price target.

See the top stocks recommended by analysts >>

BridgeBio Pharma (BBIO)

In a report released yesterday, Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma. The company’s shares closed last Tuesday at $10.80, close to its 52-week low of $7.10.

According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.0% and a 34.0% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, 4D Molecular Therapeutics, and Recursion Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Pharma with a $23.33 average price target, a 128.7% upside from current levels. In a report issued on April 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.

AN2 Therapeutics, Inc. (ANTX)

Leerink Partners analyst Joseph Schwartz initiated coverage with a Buy rating on AN2 Therapeutics, Inc. yesterday and set a price target of $27.00. The company’s shares closed last Tuesday at $14.00.

According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.0% and a 33.6% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.

AN2 Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $24.67, implying a 68.9% upside from current levels. In a report released yesterday, Cowen & Co. also initiated coverage with a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos